VEGFA and neoplasm: Inhibition of the VEGF/VEGFR pathway with Sunitinib (100 mg/kg) led to the reduction of both tumor and vessel growth by 43 (p < 0.001) (Figure 7A) and 2.5-fold (p < 0.0001) (Figure 7B) respectively compared to control.